(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 376.53% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Humacyte's revenue in 2025 is $818,000.On average, 2 Wall Street analysts forecast HUMA's revenue for 2025 to be $1,388,132,096, with the lowest HUMA revenue forecast at $1,124,442,428, and the highest HUMA revenue forecast at $1,651,821,764. On average, 2 Wall Street analysts forecast HUMA's revenue for 2026 to be $6,141,672,869, with the lowest HUMA revenue forecast at $5,215,195,657, and the highest HUMA revenue forecast at $7,068,150,081.
In 2027, HUMA is forecast to generate $14,643,091,116 in revenue, with the lowest revenue forecast at $14,391,279,361 and the highest revenue forecast at $14,894,902,871.